Results 121 to 130 of about 106,112 (301)

Treatment of a large cohort of childhood chronic non‐infectious uveitis a multicentric large study: adalimumab versus methotrexate as first line therapy

open access: yesArthritis &Rheumatology, Accepted Article.
Background Treatment of childhood chronic idiopathic uveitis (cCIU) is predominantly based on studies in Juvenile Idiopathic Arthritis associated uveitis and expert opinion. Our aim was to report the treatment outcomes of our cohort of cCIU. Methods Retrospective multicenter study involving the rheuma/ophthalmology units at Florence and Bristol.
Ilaria Maccora   +5 more
wiley   +1 more source

The Clinical Value of Inflammatory Indicators at the Time of Secondary Infection After Treatment With Tocilizumab: A Cross‐Sectional Study

open access: yesHealth Science Reports
Background and Aims Tocilizumab, an anti‐inflammatory agent used in severe COVID‐19 infection, is known to inhibit the Interleukin 6 receptor and reduce C‐reactive protein (CRP) resulting in an increased risk of secondary infections.
Dena Firouzabadi   +4 more
doaj   +1 more source

POS1200 IL-6 HIGHER LEVEL AFTER TOCILIZUMAB TREATMENT AS A PREDICTOR OF NOT-SURVIVAL IN COVID19 SEVERE PNEUMONIA: THE EXPERIENCE OF THE COVIBAS-STUDY [PDF]

open access: bronze, 2021
Michele Gilio   +12 more
openalex   +1 more source

Rheumatoid arthritis and spondyloarthropathy [PDF]

open access: yes, 2013
Part 2 of the article can be found through this link: https://www.um.edu.mt/library/oar//handle/123456789/13280Rheumatoid arthritis (RA) and spondyloarthropathy are two groups of inflammatory joint disease.
Vassallo, Pierre
core  

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel   +12 more
wiley   +1 more source

Efficacy of Tocilizumab vs. NSAIDs in the Treatment of Juvenile Rheumatoid Arthritis

open access: hybrid, 2022
Daniela I. Sánchez   +4 more
openalex   +2 more sources

The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation

open access: yes, 2016
Background: Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and limitation of movement caused by inflammation. Subsequent joint damage can lead to disability and growth restriction.
Abbvie   +171 more
core   +1 more source

Non‐Syndromic Tumefactive Demyelinating Lesions in the Pediatric Population: Four Case Reports and Review of the Literature

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Introduction Tumefactive demyelinating lesions (TDLs) are large lesions (> 2 cm) seen in demyelinating syndromes such as multiple sclerosis, myelin oligodendrocyte glycoprotein antibody‐associated disorder, and neuromyelitis optica spectrum disorder. They rarely occur in children and most often have a monophasic course.
Elizabeth C. Ballinger   +6 more
wiley   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher   +12 more
wiley   +1 more source

High Mortality Rate in Severe COVID-19 Despite Tocilizumab Administration: A Case Series

open access: yesJKS (Jurnal Kedokteran Syiah Kuala)
Introduction: Tocilizumab is a potential therapeutic agent for modulating cytokine storms, a known cause of multiorgan failure and mortality in severe COVID-19.
Cokorda Agung Wahyu Purnamasidhi   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy